Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom.
+ 3 more risks
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has OptiBiotix Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OB3's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: OB3 underperformed the German Biotechs industry which returned -1.2% over the past year.
Return vs Market: OB3 underperformed the German Market which returned -14.1% over the past year.
Price Volatility Vs. Market
How volatile is OptiBiotix Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is OptiBiotix Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OB3's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OB3's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OB3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: OB3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OB3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OB3 is overvalued based on its PB Ratio (4.3x) compared to the DE Biotechs industry average (3.6x).
How is OptiBiotix Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OptiBiotix Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of OB3’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- OptiBiotix Health competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has OptiBiotix Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OB3 is currently unprofitable.
Growing Profit Margin: OB3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OB3 is unprofitable, and losses have increased over the past 5 years at a rate of -8% per year.
Accelerating Growth: Unable to compare OB3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OB3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: OB3 has a negative Return on Equity (-33.37%), as it is currently unprofitable.
How is OptiBiotix Health's financial position?
Financial Position Analysis
Short Term Liabilities: OB3's short term assets (£1.4M) exceed its short term liabilities (£188.6K).
Long Term Liabilities: OB3's short term assets (£1.4M) exceed its long term liabilities (£1.2M).
Debt to Equity History and Analysis
Debt Level: OB3's debt to equity ratio (11.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if OB3's debt to equity ratio has reduced over the past 5 years.
Inventory Level: OB3 has a low level of unsold assets or inventory.
Debt Coverage by Assets: OB3's debt is covered by short term assets (assets are 2.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if OB3 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OB3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is OptiBiotix Health's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OB3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OB3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OB3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OB3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OB3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Stephen Patrick O'Hara Founded OptiBiotix Health plc in March 2012 and serves as its Chief Executive. He also serves as the Board Director of ProBiotix Health Limited. Mr. O'Hara served as the Chief Ex ...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD264.26K) is below average for companies of similar size in the German market ($USD429.96K).
Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.
|Founder||no data||UK£212.90k||11.82% £3.4m|
|Director of Research & Development and Executive Director||1.67yrs||UK£108.33k||no data|
|Executive Director & Managing Director of Prebiotics Division||1yr||no data||0.064% £18.7k|
|Non-Executive Director||1.5yrs||UK£7.79k||0.15% £42.7k|
|Member of Scientific Advisory Group||4.17yrs||no data||no data|
|Non-Executive Chairman||2.17yrs||UK£57.85k||0.56% £163.2k|
|Non-Executive Director||4.33yrs||UK£18.00k||no data|
Experienced Board: OB3's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.9%.
OptiBiotix Health Plc's company bio, employee growth, exchange listings and data sources
- Name: OptiBiotix Health Plc
- Ticker: OB3
- Exchange: DB
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£26.059m
- Listing Market Cap: UK£29.173m
- Shares outstanding: 85.44m
- Website: https://www.optibiotix.com
Number of Employees
- OptiBiotix Health Plc
- Innovation Centre
- Innovation Way
- North Yorkshire
- YO10 5DG
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OPTI||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Aug 2014|
|OPBX.F||OTCPK (Pink Sheets LLC)||SHS||US||USD||Oct 2015|
|OPTI||AIM (London Stock Exchange AIM Market)||ORD GBP0.02||GB||GBP||Nov 2016|
|OB3||DB (Deutsche Boerse AG)||ORD GBP0.02||DE||EUR||Nov 2016|
Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, an ingredient for use in a range of functional food products and supplements in consumer and pharmaceutical health care; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galacto oligosaccharide that are used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company’s products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/27 23:56|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.